Endpoints
tumors, PD‐L1
CPS, TUMORS
The dual primary endpoints were PFS per RECIST version 1.1 as assessed by blinded independent central review and OS in patients in the intention‐to‐treat population, patients with PD‐L1 CPS ≥10 tumors, and patients with PD‐L1 CPS ≥1 tumors. The primary endpoints were amended to include PFS and OS in patients with PD‐L1 CPS ≥10 tumors following the completion of enrollment and the first interim analysis based on data from other studies that reported increased clinical benefit with PD‐L1 enrichment.